Pfizer's Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?

Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in years.

24/7 Wall Street • Sep 4, 2026

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie has successfully pivoted to new immunology leaders to offset the loss of exclusivity for its top-selling drug. Pfizer is utilizing its robust cash position to acquire oncology assets and replenish its product pipeline.

The Motley Fool • Sep 4, 2026

3 Things You Need to Know If You Buy Pfizer Stock Today

Investors won't start seeing the fruits of Pfizer's current efforts for several more years. A handful of its top-selling drugs will be losing their patent protection in the meantime.

The Motley Fool • Sep 3, 2026

Pfizer's Pipeline Strategy Centers on Obesity and Oncology

PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.

Zacks Investment Research • Sep 3, 2026

Pfizer (PFE) Up 12.4% Since Last Earnings Report: Can It Continue?

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 3, 2026

Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion

Medicus Pharma Ltd. (NASDAQ:MDCX) secured on Wednesday an exclusive, sublicensable global license from Pfizer Inc. (NYSE:PFE) to develop, manufacture, and commercialize PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate targeting melanotransferrin.

Benzinga • Sep 3, 2026

Should You Buy Pfizer Stock Below $30?

Pfizer's financial results aren't great, and the company will face important patent cliffs relatively soon. However, the company may have a deep enough pipeline to supercharge top-line growth.

The Motley Fool • Sep 2, 2026

Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities

"I'll give you 950 billion reasons to buy bonds right now," says Thomas Hayes, who gives a contrarian take on why investors should bolster their portfolios in fixed income. He discusses the "seasonality effect," a crowded AI trade, a complicated geopolitical picture, and a steady rise in crude oil as components he sees leading a lasting bond rally.

Trump administration to announce drug pricing deals

U.S. President Donald ​Trump is expected to announce a new round of drug-pricing agreements on Monday, a White ‌House official said, part of a push to make healthcare more affordable for Americans.

Reuters • Aug 31, 2026

From Padcev to PF-08634404: Pfizer's Oncology Growth Push

PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.

Zacks Investment Research • Aug 31, 2026